Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 614

Sort by

Sort Order Select

Journal Articles

Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity

Blood (2021) 138 (14): 1225–1236.

https://doi.org/10.1182/blood.2020009655

Published: 2021

Includes: Supplemental data

Journal Articles

PD-1 loss and T-cell exhaustion in CTCL tumoral T cells

Margarita Sánchez-Beato

Blood (2021) 138 (14): 1201–1203.

https://doi.org/10.1182/blood.2021012676

Published: 2021

Journal Articles

Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia and Provides a Potential Therapeutic Approach Using 5-Azacitidine

Jonathan E Brammer, MD, Amy E Boles, BS, Anthony Mansour, MD, Aharon G. Freud, MD PhD, Monique Mathé-Allainmat, Agnès Quéméner, Erwan Mortier, Pierluigi Porcu, MD, Anjali Mishra, PhD

Blood (2019) 134 (Supplement_1): 3776.

https://doi.org/10.1182/blood-2019-131174

Published: 2019

Journal Articles

Aberrant SYK Expression As a Potential Therapeutic Target in T/NK Cell Neoplasms

Jing-Ping Zhang, PhD, Qi Gao, MLS, Alexander Chan, MD, Wenbin Xiao, MD PhD, Sary El Daker, PhD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD

Blood (2019) 134 (Supplement_1): 3978.

https://doi.org/10.1182/blood-2019-130406

Published: 2019

Journal Articles

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4019.

https://doi.org/10.1182/blood-2019-125017

Published: 2019

Journal Articles

Primary Cutaneous Anaplastic Large-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis from 2005-2016

Cesar Gentille Sanchez, MD, Joe Ensor, PhD, Akshjot Puri, MD, Jasleen K. Randhawa, MD, Shilpan S. Shah, MD, Sai Ravi Kiran Pingali, MD

Blood (2019) 134 (Supplement_1): 4022.

https://doi.org/10.1182/blood-2019-131991

Published: 2019

Journal Articles

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

Christiane Querfeld, MD PhD, Xiwei Wu, PhD, Tracy Stiller, MS, Joycelynne Palmer, PhD, James F Sanchez, PhD, Xochiquetzal Martinez, MD, Steven Rosen, MD, Jasmine Zain, MD

Blood (2019) 134 (Supplement_1): 4024.

https://doi.org/10.1182/blood-2019-126358

Published: 2019

Journal Articles

Mortality and Risk Factors for Bacteremia in Patients with Cutaneous T-Cell Lymphoma (CTCL) at Emory University

Pamela Allen, MDMSc, Esther Kim, Amy Ayers, MPH, Mary Jo Lechowicz, MD

Blood (2019) 134 (Supplement_1): 4043.

https://doi.org/10.1182/blood-2019-131626

Published: 2019

Journal Articles

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4032.

https://doi.org/10.1182/blood-2019-121723

Published: 2019

Journal Articles

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Mehrdad Mobasher, MD MPH, Richard A. Miller, MD, James W. Janc, PhD, Long Kwei, PhD, Joseph J. Buggy, PhD, Gabriel Luciano, Anahita Mohammady, PharmD, Won Seog Kim, MD PhD, Youn H. Kim, MD, Michael S. Khodadoust, MD PhD, Steven M. Horwitz, MD, Dejan Radeski, MBBS, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4030.

https://doi.org/10.1182/blood-2019-124958

Published: 2019

Journal Articles

A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4033.

https://doi.org/10.1182/blood-2019-124179

Published: 2019

Journal Articles

Diagnostic 2-Gene Classifier in Early-Stage Mycosis Fungoides: A Retrospective Multicenter Study

Pia Rude Nielsen, MD, Jens Ole Eriksen, MSc, PhD, Lise M. Lindahl, MD PhD, Ulrike Wehkamp, MD, Gitte Rinds Andersen, MSc, PhD, Michael Bzorek, Kirsten Grønbæk, Professor, MD DMSc, Niels Odum, MD DMSci, Thomas Litman, Prof., Lise Mette Rahbek Gjerdrum, MD PhD

Blood (2019) 134 (Supplement_1): 2772.

https://doi.org/10.1182/blood-2019-122031

Published: 2019

Journal Articles

Baseline Total Lesion Glycolysis Combined with Interim PET/CT Is a Robust Predictor of Outcome in Patients with Peripheral T-Cell Lymphoma

Akihiro Kitadate, MD PhD, Kentaro Narita, MD, Kota Fukumoto, MD, Toshiki Terao, MD, Takafumi Tsushima, MD, Hiroki Kobayashi, MD, Yoshiaki Abe, MD, Daisuke Miura, MD, Masami Takeuchi, MD, Youichi Machida, MD, Naoto Takahashi, MD PhD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 2839.

https://doi.org/10.1182/blood-2019-122799

Published: 2019

Journal Articles

Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

Blood (2019) 134 (Supplement_1): 2844.

https://doi.org/10.1182/blood-2019-129664

Published: 2019

Journal Articles

Single-Antibody Detection of T-Cell Receptor Beta Chain Monotypia Resolves Uncertainties in the Identification and Quantitation of Sézary Cells By Routine Flow Cytometry: Towards Accurate and Unequivocal Blood Staging of Cutaneous T-Cell Lymphomas

Pedro Horna, MD, Min Shi, MD PhD, Dragan Jevremovic, MD PhD, Horatiu Olteanu, MD PhD

Blood (2019) 134 (Supplement_1): 2848.

https://doi.org/10.1182/blood-2019-129477

Published: 2019

Journal Articles

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Basem M. William, MRCP,MD, Ying Huang, MS, MA, Amy Johnson, MD, Jonathan E Brammer, MD, John C. Reneau, MD PhD, Joseph Maakaron, MD, Ruth Larbi, Cara Grantier, CNP, MPH, MS, Corinne Hoffman, MS, CNP, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MDMS, Beth A. Christian, MD, Lapo Alinari, MD PhD, Kami J. Maddocks, MD, Catherine Chung, MD

Blood (2019) 134 (Supplement_1): 2853.

https://doi.org/10.1182/blood-2019-123801

Published: 2019

Journal Articles

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Swaminathan P. Iyer, MD, Brad M. Haverkos, MDMPH,MS, Jasmine Zain, MD, Radhakrishnan Ramchandren, MD, Mary Jo Lechowicz, MD, Sumana Devata, MD, Neil Korman, MD, Lauren C. Pinter-Brown, MD, Kasi Viswanath Routhu, PhD, Prajak Barde, MD, Ajit Mohanchandran Nair, PhD, Auris Huen, MD

Blood (2019) 134 (Supplement_1): 2831.

https://doi.org/10.1182/blood-2019-123954

Published: 2019

Journal Articles

Outcome of Autologous Hematopoietic Cell Transplantation in First Complete Remission(CR1) in Patients with Peripheral T-Cell Lymphomas(PTCLs)

Shuo Liu, Zhengming Jin, Depei Wu, MD PhD, Haiwen Huang, MD PhD

Blood (2019) 134 (Supplement_1): 3315.

https://doi.org/10.1182/blood-2019-125666

Published: 2019

Journal Articles

Efficacy of Methoxsalen Sterile Solution in Conjunction with the Therakos ® Cellex ® Photopheresis System in Pediatric Patients with Steroid-Refractory Acute GvHD: Interim Analysis

Carrie Kitko, MD, Stefania Gaspari, MD, Henri Boodée

Blood (2019) 134 (Supplement_1): 4524.

https://doi.org/10.1182/blood-2019-124061

Published: 2019

Journal Articles

A Prospective Cohort of Black Patients with Mycosis Fungoides and Sézary Syndrome: Subset Analysis of the Mavoric Trial

William T Johnson, DO, Saritha Kartan, MD, Neda Nikbakht, MD PhD, Pierluigi Porcu, MD

Blood (2019) 134 (Supplement_1): 4766.

https://doi.org/10.1182/blood-2019-126313

Published: 2019

NARROW

Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity

PD-1 loss and T-cell exhaustion in CTCL tumoral T cells

Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia and Provides a Potential Therapeutic Approach Using 5-Azacitidine

Aberrant SYK Expression As a Potential Therapeutic Target in T/NK Cell Neoplasms

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Primary Cutaneous Anaplastic Large-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis from 2005-2016

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

Mortality and Risk Factors for Bacteremia in Patients with Cutaneous T-Cell Lymphoma (CTCL) at Emory University

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma

Diagnostic 2-Gene Classifier in Early-Stage Mycosis Fungoides: A Retrospective Multicenter Study

Baseline Total Lesion Glycolysis Combined with Interim PET/CT Is a Robust Predictor of Outcome in Patients with Peripheral T-Cell Lymphoma

Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

Single-Antibody Detection of T-Cell Receptor Beta Chain Monotypia Resolves Uncertainties in the Identification and Quantitation of Sézary Cells By Routine Flow Cytometry: Towards Accurate and Unequivocal Blood Staging of Cutaneous T-Cell Lymphomas

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Outcome of Autologous Hematopoietic Cell Transplantation in First Complete Remission(CR1) in Patients with Peripheral T-Cell Lymphomas(PTCLs)

Efficacy of Methoxsalen Sterile Solution in Conjunction with the Therakos ® Cellex ® Photopheresis System in Pediatric Patients with Steroid-Refractory Acute GvHD: Interim Analysis

A Prospective Cohort of Black Patients with Mycosis Fungoides and Sézary Syndrome: Subset Analysis of the Mavoric Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only